Description

Peptron, Inc. specializes in the creation of peptide-based pharmaceuticals designed to manage chronic health conditions. The company's technological expertise encompasses advanced long-acting drug delivery systems and SmartDepot, an ultrasonic spray-drying technique utilized for developing sustained-release injectable microsphere drug formulations. Their research and development pipeline features several key products: Luphere Depot, which addresses prostate cancer, endometriosis, uterine fibroids, and puberty-related issues; SR-Octreotide (PT201) for treating acromegaly; SR-Exenatide (PT302) for type 2 diabetes; and SR-Exenatide (PT320), which is aimed at Parkinson's and Alzheimer's diseases. Founded in 1997, Peptron, Inc. is headquartered in Daejeon, South Korea.